CU20100143A7 - Hormonas de administración transdérmica que no necesitan potenciadores de penetración - Google Patents

Hormonas de administración transdérmica que no necesitan potenciadores de penetración

Info

Publication number
CU20100143A7
CU20100143A7 CU2010000143A CU20100143A CU20100143A7 CU 20100143 A7 CU20100143 A7 CU 20100143A7 CU 2010000143 A CU2010000143 A CU 2010000143A CU 20100143 A CU20100143 A CU 20100143A CU 20100143 A7 CU20100143 A7 CU 20100143A7
Authority
CU
Cuba
Prior art keywords
hormones
patch
potentiators
transdermal administration
need
Prior art date
Application number
CU2010000143A
Other languages
English (en)
Other versions
CU23868B1 (es
Inventor
Stefan Bracht
Michael Dittgen
Petra Huber
Thomas Langguth
Dirk Schenk
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34702342&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20100143(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CU20100143A7 publication Critical patent/CU20100143A7/es
Publication of CU23868B1 publication Critical patent/CU23868B1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7076Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

La invención se refiere a un parche que comprende una capa de droga con un bajo contenido de hormonas, como por ejemplo gestodeno, y opcionalmente un estrógeno (por ejemplo etinilestradiol). Al aplicar el parche a una mujer, se consiguen niveles en plasma de al menos 1,0 ng/ml de gestodeno en condiciones de estado estacionario sin necesidad de incorporar potenciadores de penetración ni mejoradores de permeación en la capa que contiene droga. También son satisfactorios los niveles en plasma de las hormonas que se consiguen durante todo un periodo de al menos una semana, haciendo que el parche se pueda aplicar para utilizarlo en anticoncepción femenina con el concepto de aplicar el parche una vez a la semana.
CU20100143A 2003-12-12 2010-07-05 Hormonas de administración transdérmica que no necesitan potenciadores de penetración CU23868B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52871803P 2003-12-12 2003-12-12
EP03078881 2003-12-12
PCT/IB2004/052752 WO2005058287A2 (en) 2003-12-12 2004-12-10 Transdermal delivery system of hormones without penetration enhancers

Publications (2)

Publication Number Publication Date
CU20100143A7 true CU20100143A7 (es) 2011-10-31
CU23868B1 CU23868B1 (es) 2013-03-27

Family

ID=34702342

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20100143A CU23868B1 (es) 2003-12-12 2010-07-05 Hormonas de administración transdérmica que no necesitan potenciadores de penetración

Country Status (15)

Country Link
JP (1) JP4965263B2 (es)
KR (1) KR101168449B1 (es)
CN (1) CN1913878B (es)
AU (1) AU2004298930B2 (es)
BR (1) BRPI0417530B8 (es)
CA (1) CA2549916C (es)
CU (1) CU23868B1 (es)
EA (1) EA011160B1 (es)
EC (1) ECSP066694A (es)
IL (1) IL176112A (es)
MX (1) MXPA06006682A (es)
NO (1) NO341989B1 (es)
NZ (1) NZ548091A (es)
WO (1) WO2005058287A2 (es)
ZA (1) ZA200605713B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100704825B1 (ko) 2003-02-21 2007-04-09 바이엘 쉐링 파마 악티엔게젤샤프트 Uv 안정성 경피 치료 플라스터
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
DE102005050729A1 (de) * 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
FR2900048B1 (fr) * 2006-04-21 2012-11-16 Oreal Compositions comprenant un derive diphenyl-methane hydroxyle
AU2015203180B2 (en) * 2010-09-06 2016-06-30 Bayer Intellectual Property Gmbh Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)
DE102010040299A1 (de) * 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
WO2012031999A2 (en) 2010-09-06 2012-03-15 Bayer Pharma Aktiengesellschaft Low-dose transdermal patches with high drug release
EP2806862A2 (en) * 2012-01-27 2014-12-03 Agile Therapeutics, Inc. Transdermal hormone delivery
HK1251938A1 (zh) * 2015-05-18 2019-05-03 敏捷治疗公司 避孕组合物及提高效能和调节副作用的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0394429B1 (de) * 1988-10-27 1996-01-10 Schering Aktiengesellschaft Mittel zur transdermalen applikation enthaltend gestoden
US5512292A (en) * 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
NZ240358A (en) * 1990-10-29 1994-09-27 Alza Corp Transdermal contraceptive device comprising (as active agents) an estrogen and a gestodene together with a skin permeation enhancer
DE4329242A1 (de) * 1993-08-26 1995-03-02 Schering Ag Mittel zur transdermalen Applikation enthaltend Gestodenester
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
KR970706805A (ko) * 1994-11-18 1997-12-01 나까토미 히로타카 경피흡수첩부제(percutaneously absorbable patch)
CN1188189C (zh) * 1995-06-07 2005-02-09 奥瑟-麦内尔制药公司 基质层含有17-脱乙酰基诺孕酯的经皮贴片及基质的用途
JP4346696B2 (ja) * 1996-05-28 2009-10-21 久光製薬株式会社 経皮治療用装置
JP4167750B2 (ja) * 1997-04-16 2008-10-22 久光製薬株式会社 経皮吸収用基剤及び該基剤を含有する経皮吸収製剤
JP4399044B2 (ja) * 1998-10-14 2010-01-13 久光製薬株式会社 吸収促進剤及び該吸収促進剤を有してなる経皮吸収製剤
DE19906152B4 (de) * 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
WO2001001990A1 (en) * 1999-07-01 2001-01-11 Hisamitsu Pharmaceutical Co., Inc. Adhesive preparation for percutaneous absorption
DE10053375C1 (de) * 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen
AU2002235155A1 (en) * 2000-12-05 2002-06-18 Noven Pharmaceuticals, Inc. Crystallization inhibition of drugs in transdermal drug delivery systems

Also Published As

Publication number Publication date
CN1913878A (zh) 2007-02-14
EA011160B1 (ru) 2009-02-27
NO341989B1 (no) 2018-03-12
CA2549916C (en) 2013-09-17
KR20060128910A (ko) 2006-12-14
BRPI0417530B8 (pt) 2021-05-25
JP2007513938A (ja) 2007-05-31
NO20062594L (no) 2006-07-10
EA200601089A1 (ru) 2006-12-29
ECSP066694A (es) 2006-10-31
IL176112A0 (en) 2006-10-05
CA2549916A1 (en) 2005-06-30
AU2004298930B2 (en) 2009-11-26
CN1913878B (zh) 2010-05-26
CU23868B1 (es) 2013-03-27
MXPA06006682A (es) 2006-08-11
KR101168449B1 (ko) 2012-07-25
AU2004298930A1 (en) 2005-06-30
WO2005058287A2 (en) 2005-06-30
JP4965263B2 (ja) 2012-07-04
IL176112A (en) 2011-02-28
ZA200605713B (en) 2008-01-08
NZ548091A (en) 2009-12-24
BRPI0417530A (pt) 2007-03-13
WO2005058287A3 (en) 2006-03-02
BRPI0417530B1 (pt) 2018-01-23

Similar Documents

Publication Publication Date Title
CU20100143A7 (es) Hormonas de administración transdérmica que no necesitan potenciadores de penetración
CY1115064T1 (el) Διαδερμικο συστημα παραδοσης ορμονων χωρις ενισχυτες διεισδυσης
NO993520L (no) Doseringsformer og fremgangsmÕte for Õ bedre erektil dysfunksjon
ATE329586T1 (de) Zusammensetzungen enthaltend carotenoide und deren verwendung zur verhinderung hormon- induzierter nebenwirkungen
ES2190472T3 (es) Parche transdermico para la administracion de 17-deacetil norgestimato, solo o en combinacion con un estrogeno.
BR0312007A (pt) Controle de taxa de administração transcutânea usando composições farmacêuticas amorfas
CR7610A (es) Uso de derivados de thio-oxindol en el tratamiento de condiciones realcionadas con la hormona
MXPA04005211A (es) Sistemas terapeuticos transdermicos que contienen hormona esteroides y monocaprilato de propilenglicol.
MX2022008277A (es) Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas.
ATE382356T1 (de) Pharmazeutische zusammensetzung enthaltend estetrolderivate und anwendung in der krebsbehandlung
CU23264B7 (es) Preparados de liberacion retardada de antibioticos de quinolona y procedimiento para su preparacion
AR021459A1 (es) PARCHE QUE CONTIENE ESTRADIOL PARA LA APLICACIoN PERCUTÁNEA DE HORMONAS.
UY28668A1 (es) Hormonas de administración transdérmica que no necesitan potenciadores de penetración
AR049197A1 (es) Anticonceptivo hormonal conteniendo una combinacion de etinilestradiol y acetato de clormadinona
CU20060121A7 (es) Hormonas de administración transdérmica que no necesitan potenciadores de penetración
CR8059A (es) Composicion farmaceutica en forma de hidrogel para administracion transdermica de sustancias activas
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.
PE20070119A1 (es) Nuevos regimenes para dispositivos de suministro controlado de farmacos para la anticoncepcion
ATE269063T1 (de) Formulierungen zur transdermalen verabreichung von fenoldopam
PL359235A1 (en) Therapeutic agent

Legal Events

Date Code Title Description
FG Grant of patent